7 documents found, page 1 of 1
Tratamento do Cancro da Mama HER2-Positivo: Posicionamento de um Painel de Peritos
Afonso, Noémia; Cortes, Paulo; Cardoso, Fátima; Costa, Luís; Coutinho, Camila; Moreira, António; Passos Coelho, José Luís; Pereira, DeolindaThe overexpression of the human epidermal growth factor receptor type 2 (HER2) is present in 20% of all breast cancers and has known prognostic value, associated with a higher risk of recurrence and mortality. Management of these patients has evolved significantly in recent years due to advances in the identification of biomarkers and in treatment efficacy. This article reviews key aspects of the neoadjuvant an...
Retomar, criar e elevar
Cortes, Paulo; Afonso, Noémia.
The treatment of liver metastases in patients with neuroendocrine tumors in 2012
Macedo, Daniela; Amaral, Teresa; Fernandes, Isabel; Sousa, Ana Rita; Costa, Ana Lúcia; Távora, Isabel; Quintela, António; Cortes, Paulo; Costa, LuisNeuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75-80% of patients present with liver metastases at the time of their diagnosis, and 20%-25% will develop these lesions in the course of their disease. The presence of secondary deposits in the liver significantly increases the morbidity and mortality in these patients. The only potentially curative ...
Cancro Ginecológico – consensos nacionais 2013
Pregal, Alexandra; Sofia, Alexandra Rico; Petiz, Almerinda; Félix, Ana; Jorge, Ana Francisca; Costa, Ana Marta; Lagoa, António; Alves, Boaventura
Treatment Options in Metastatic Gastroenteropancreatic (GEP NETS) Neuroendocrin...
Fernandes, Isabel; Amaral, Teresa; Macedo, Daniela; Cortes, Paulo; Costa, LuísNeuroendocrine tumors are relatively rare neoplasias with a large clinical presentations and outcomes. In the metastatic disease multiple therapeutic approaches are possible in order to improve quality of life and extend survival. In this review we will provide an update of treatment options routinely used in the management of advanced gastroenteropancreatic neuroendocrine tumors (GEP NETS) such as medical and ...
Cost of cancer care in Portugal.
Araújo, António; Barata, Fernando; Barroso, Sérgio; Cortes, Paulo; Damasceno, Margarida; Parreira, António; Espírito Santo, Jorge; Teixeira, EncarnaçãoCancer is the second most important cause of death in Portugal, following cardiovascular diseases (CVD), and shows a constant progressive increase in the proportional share of total deaths. In Portugal, as in most countries, the health care budget is under constant cost-containment pressures. In this context it is necessary to verify if enough resources have been allocated to the disease in terms of health care...